OS Therapies filed a prospectus supplement for the resale of up to 10,529,417 shares of common stock by selling stockholders, covering shares issuable upon warrant exercise and note conversion.
Key takeaways
The filing covers the resale of 10,529,417 shares of common stock by selling stockholders.
The shares consist of 4,289,441 Warrant Shares and 6,239,976 Conversion Shares.
The prospectus supplement relates to an effective S-3 registration statement filed on August 8, 2025.
The Company received requisite approval from NYSE American to list the Warrant Shares and Conversion Shares.
Olshan Frome Wolosky LLP provided a legal opinion confirming the validity of the shares.